Zacks Research Has Bearish Forecast for GSK FY2025 Earnings

GSK plc (NYSE:GSK) – Stock analysts at Zacks Research reduced their FY2025 EPS estimates for shares of GSK in a research report issued on Wednesday, October 16th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings of $4.45 per share for the year, down from their previous estimate of $4.51. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $0.96 EPS, Q3 2026 earnings at $1.55 EPS and FY2026 earnings at $4.96 EPS.

GSK (NYSE:GSK) last released its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. The firm had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%.

Other analysts also recently issued research reports about the company. Jefferies Financial Group raised their price objective on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Barclays raised shares of GSK to a “hold” rating in a research note on Tuesday, August 27th. Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Citigroup upgraded shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $50.00.

GSK Stock Down 1.1 %

GSK stock opened at $38.55 on Monday. The company’s 50 day simple moving average is $41.44 and its 200 day simple moving average is $41.25. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. The firm has a market capitalization of $79.89 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 1.30 and a beta of 0.65. GSK has a fifty-two week low of $33.67 and a fifty-two week high of $45.92.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Investors of record on Friday, August 16th were issued a dividend of $0.3843 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, August 16th. This represents a $1.54 annualized dividend and a yield of 3.99%. GSK’s dividend payout ratio is presently 55.80%.

Insider Activity at GSK

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the firm’s stock in a transaction dated Friday, September 27th. The stock was bought at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.00% of the stock is owned by insiders.

Institutional Investors Weigh In On GSK

Large investors have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its stake in GSK by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 1,043,624 shares of the pharmaceutical company’s stock valued at $38,677,000 after acquiring an additional 131,021 shares during the last quarter. &PARTNERS acquired a new position in GSK during the first quarter worth approximately $299,000. AdvisorNet Financial Inc raised its stake in GSK by 1.6% in the first quarter. AdvisorNet Financial Inc now owns 21,053 shares of the pharmaceutical company’s stock valued at $903,000 after buying an additional 324 shares during the period. Range Financial Group LLC boosted its stake in shares of GSK by 11.3% during the 1st quarter. Range Financial Group LLC now owns 11,019 shares of the pharmaceutical company’s stock worth $472,000 after acquiring an additional 1,117 shares during the period. Finally, Gilman Hill Asset Management LLC increased its holdings in shares of GSK by 5.2% during the 1st quarter. Gilman Hill Asset Management LLC now owns 57,452 shares of the pharmaceutical company’s stock worth $2,463,000 after acquiring an additional 2,857 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.